GMED — GLOBUS MEDICAL INC - US
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying GMED?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 1 tracked investors who changed their GMED position last quarter, 1 bought and 0 sold (100% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 56/100 in a Overheat regime).
- +1 tracked investor added or increased positions last quarter (Ray Dalio)
- +3 tracked investors reported holding GMED at their latest filing
- +Macro Health is 56/100 in a Overheat regime — historically acceptable for this sectorsource
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.
About GLOBUS MEDICAL INC - US (GMED)
GLOBUS MEDICAL INC - US (GMED) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $219M. Across recent filings, tracked investors recorded 5 new positions, 6 increased, 6 reduced, and 4 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in GMED
How many top investors track GMED
A small number of top investors own this.
GMED Ownership Composition
How GLOBUS MEDICAL INC - US is held across tracked investor types, based on reported 13F positions.
- Macro78.9%
- Multi-Strategy / Quant21.1%
Tracked investors currently reporting GMED
2 tracked investors have since exited this position — listed separately below.
- Ken GriffinJun 30, 2026Citadel AdvisorsShares65.4KValue$5.2M% Portfolio0.00%
- Izzy EnglanderJun 30, 2026Millennium ManagementShares28.8KValue$2.3M% Portfolio0.00%
- Ray DalioJun 30, 2026Bridgewater AssociatesShares352KValue$27.8M% Portfolio0.11%
Previously held GMED
These investors reported GMED in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.
| Investor | Firm | Last reported shares | Value then | Last held |
|---|---|---|---|---|
| Steve Cohen | Point72 Asset Management | 591.7K | $48.9M | Dec 31, 2024 |
| Paul Tudor Jones | Tudor Investment Corp | 83.3K | $7.3M | Dec 31, 2025 |
Recent activity
- Reduced$5.8M(-22.89%)Feb 14, 2024
- Reduced$1.7M(-71.66%)May 14, 2024
- Increased$8.9M(317.66%)Aug 14, 2024
- Reduced$2.4M(-74.60%)Nov 13, 2024
- Sold$0(-100.00%)Feb 13, 2025
- New$9.7MMay 14, 2025
- Increased$25.8M(228.02%)Aug 13, 2025
- Sold$0(-100.00%)Nov 13, 2025
- New$27.8MAug 14, 2026
- New$10.4MNov 14, 2024
- Increased$48.9M(306.47%)Feb 14, 2025
- Sold$0(-100.00%)Jul 21, 2025
- Increased$5.5M(1408.14%)Aug 14, 2024
- Increased$11.9M(106.50%)Nov 14, 2024
- Reduced$8.8M(-36.01%)Feb 14, 2025
- Increased$7.9M(1.77%)May 15, 2025
- Reduced$6.1M(-4.08%)Aug 14, 2025
- Reduced$5.7M(-3.38%)Dec 9, 2025
- Sold$0(-100.00%)May 15, 2026
- New$7MNov 13, 2023
- $285.4KMay 15, 2024
Frequently asked questions
- How many institutional investors hold GMED?
- 3 tracked institutional investors disclosed a position in GMED (GLOBUS MEDICAL INC - US) in their most recent 13F filing.
- Who is the largest institutional holder of GMED?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in GMED, valued at $219M.
- Did institutional ownership of GMED increase or decrease?
- Across recent 13F filings, tracked investors recorded 5 new positions, 6 increased, 6 reduced, and 4 fully exited GMED.
- Where does this GMED ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.